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ABSTRACT
Objectives: The role of human papilloma virus (HPV) in the development of cancerous states of female reproductive tract 
has been widely debated. However, the information about presence of HPV in the Caucasian women living in the central 
Europe diagnosed with vulvar intraepithelial neoplasia (VIN) is missing. So far, no recommendation was made to complete 
HPV detection in time of vulvar biopsy or after the results of positive VIN are obtained. We aimed to assess the presence of 
HPV in women with vulvar intraepithelial neoplasia diagnosed at the Department of Gynecology, Obstetrics and Oncologi-
cal Gynecology in Bytom, Poland.
Material and methods: The retrospective examination of 120 consecutive vulvar biopsies obtained from women with 
persistent vulvar itching was done. Only patients with diagnosis of VIN were included in the further analysis. HPV DNA 
was detected using HPV Linear Array Genotyping Test including 14 HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59, 66, 68).
Results: Out of 120 vulvar samples retrieved, 18 women were positive for VIN, including15 usual VIN (uVIN) and three dif-
ferentiated type (dVIN ). 10 samples were eligible for DNA detection. HPV DNA was found in two women with uVIN (HPV 
16 and 51).
Conclusions: It is advisable to recommend HPV genotyping in women with VIN, regardless of their age and histologic type. 
The incidence of HPV infection in Caucasian women from the central Europe with VIN should be further studied.
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INTRODUCTION
Human Papilloma Virus (HPV) infection has been identi-
fied as an important factor for subsequent carcinogenesis in 
women of all ages [1, 2]. In recent decades, the incidence of 
vulvar intraepithelial neoplasia (VIN) increased with concur-
rent decrease in the age of women suffering from this disease 
[3]. It is a premalignant vulvar skin disorder that often causes 
severe and long-lasting pruritus, pain and psychosexual 
dysfunction. HPV– associated VIN is the most common in 
women from 30 to 40 years old [4]. Previous data from Poland 
show 15% prevalence of HPV in vulvar cancer tissue with 
a predominant type 16 (71%), which was recently underlined 
in report by Nowakowski et al. [5, 6]. In the Estonian study, 
high-risk HPV (16, 18, 31, 33, 45, 52, 58) was present in 90% 
of vulvar cases [7]. In Czech, as many as 37% of randomly 
enrolled women were detected positive for HPV during the 
observational vaccination study [8]. Recent Austrian study 
showed 23% of vulvar cancers had been HPV positive, with 
more than 90% of them being a single-type infection [9]. 
Objectives
There is a gap in reporting of HPV detection among 
Caucasian women from central Europe with vulvar intraepi-
thelial neoplasia. Currently, it is not a standard procedure 
to evaluate HPV status in time of vulvar biopsy. Thus, we 
retrospectively evaluated vulvar samples obtained during 
diagnosis of persistent vulvar itching, with special focus on 
VIN patients. 
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MATERIAL AND METHODS
Material 
The study included 120 subsequent vulvar biopsies 
obtained from women undergoing vulvar sampling due 
to persistent vulvar itching (more than six months). The 
Ethics Committee of Medical University of Silesia granted 
the permission for this study. Only patients with positive 
diagnosis of VIN were included in further HPV genotyping. 
Two paraffin blocks were used for further processing 
and one was used as back-up sample. At least, two paraffin 
sections were systemically obtained for each paraffin block. 
Methods
Pathologic diagnosis
Pathology review was done by an experienced patholo-
gist (B.D.) and confirmed by immunohistochemistry.
Sections (4 µm) from formalin-fixed, paraffin-embedded 
tissues were cut and placed on salinized slides. Following 
deparaffinization in xylene, slides were rehydrated in graded 
alcohol and washed in deionized water. Antigen retrieval 
was performed by cooking slides for 20 minutes at 95°C in 
Heat-Induced Epitope Retrieval Buffer (Thermo Scientific, 
Fremont, USA): for p16 — pH6, for p53 — pH9. Endog-
enous peroxidase activity was blocked with 3% hydrogen 
peroxidase. To block the possibility of non-specific binding 
of antibodies to other proteins, sections were incubated 
with Protein Block (Thermo Scientific) for 5 minutes. Then, 
slides were incubated in humidified chamber with primary 
antibodies: p16 INK4A (MX007 clone, dilution 1:200, Immu-
nologic, Netherlands) for 40 minutes at room temperature, 
p53 (D07 clone, dilution 1:300, Cell Marque, USA) for 30 min-
utes at room temperature. After washing with Tris-buffered 
saline 3 times for 3 minutes, the sections were treated with 
Primary Antibody Amplifier Quanto and then HRP Polymer 
Quanto (Thermo Scientific). For the visualization was used 
3-3´-diaminobenzidine DAB Quanto (Thermo Scientific). Fi-
nally, tissue sections were counterstained with hematoxylin, 
dehydrated and covered with coverslips. 
Based on extent of immunolabeling, p16 (nuclear and cy-
toplasmic staining) and p53 (nuclear staining) immunoexpres-
sions were recorded as positive (+), focal positive or negative (–).
DNA extraction
DNA from FFPE samples was isolated according to the 
protocol of the supplier of AllPrep DNA/RNA FFPE Kit (Qia-
gen, Germany). Briefly, three sections of the paraffin sample 
block were deparaffinized with xylene, and then lysed with 
PKD buffer and proteinase K for 30 min. After isolation of 
total RNA, DNA was extracted with additional lysis step with 
ATL Buffer and proteinase K. Elution of DNA was done with 
supplier buffer ATE. DNA concentrations were determined 
using spectrophotometer (Nanodrop2000, ThermoScien-
tific, USA). The amount and quality of the obtained DNA 
was poor. 
Subsequently, for removal of all organic solvents, DNA 
was purified with Agencourt AMPure XP solution (Beck-
man Coulter, USA).
HPV genotyping
Multiple, simultaneous, detection of 37 HPV genotypes 
on archival tissues was conducted with the use of Linear 
Array HPV genotyping test (Roche Diagnostics, Germany). 
For diagnostic purposes test is validated only on specimens 
collected in cobas® PCR Cell Collection Media or PreservCyt 
Solution. The sensitivity of this test was also confirmed previ-
ously on frozen tissues, when compared with conventional 
PCR/sequencing [10]. Here, we attempt to use the test on 
archival FFPE samples. From 50 ng to 500 ng of DNA were 
tested for high- and low-risk HPV DNA according to the manu-
facturer’s protocol with exemption of specimen preparation, 
which was done as already described above. The rest of the 
procedure was conducted exactly as recommended by the 
manufacturer of Linear Array HPV Genotyping and Detection 
kit. Briefly, 50 µL of DNA was mixed with 50 µL od Master Mix 
comprising, inter alia, AmpliTaq Gold DNA Polymerase and 
pool of biotinylated primers to polymorphic L1 region of the 
HPV genome that are designed to amplify 13 high risk and 
24 low risk HPV genotypes. The amplification reaction was set 
on 96-Well GeneAmp PCR System 9700 (Applied Biosystems, 
USA). After amplification denaturing solution (DN) was added 
to PCR products. Denatured amplicons were hybridized on to 
the strips containing specific probes for HPV genotypes and 
β-globin reference genes and detected with the colorimetric 
reaction with Streptavidin-horseradish peroxidase. Positive 
reactions were visualized as blue bands on the strip. 
RESULTS
Pathology review revealed 18 (18/120; 15%) patients 
who were diagnosed with vulvar intraepithelial neoplasia. 
After DNA extraction from embedded tissue in paraffin, only 
10 samples (10/18; 55%) were eligible for further HPV geno-
typing. Table 1 presents procedures that were undertaken 
in cases of primarily failed DNA detection for 8 patients.  
Table 2 presents detailed analysis of each patient status 
including their age, p16 and p53 staining, HPV presence. Out of 
ten samples, two (20%) were positive for high-risk HPV: 16 and 
51. Figure 1 presents example of positive genotyping for HPV 51. 
DISCUSSION
Results of this study indicate the need of assessment of 
HPV status at time of VIN diagnosis. The reported incidence 
of HPV in our group is slightly higher than in the previous 
Polish report (20% vs 15%) [5], but remains comparable to 
those presented by Austrian research (20% vs 23%) [9]. It is 
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below another world-wide report, which showed that 86% of 
VIN2/3 cases had been HPV positive or 87% in all VIN [11, 12]. 
It is noteworthy, that 7 of 10 patients in our group had 
VIN1 according to the previous classification, so this may 
explain existing differences. 
What is very important is we avoided previous limitation 
to use separate biopsies for pathology and HPV analysis and 
we simultaneously controlled for p16 and p53 staining [3]. 
The increase in p16 protein production is linked to elevated 
transcription mediated by high-risk HPV-encoded oncopro-
tein E7 which inactivates Rb protein, releasing p16 from neg-
ative feedback control [13]. Yet, in our analysis both women 
with positive high-risk HPV had negative staining for p16. 
Another strength of this study is that we did not limit 
our inclusion criteria to one histological type of VIN [14].
Major limitation is the use of embedded vulvar tissue 
requiring multiple steps to obtain sample available for HPV 
genotyping. This may lead to unexposed HPV and underes-
timation of results. Similar methodological approach using 
PapilloCheck microarray was previously presented and it has 
shown prevalence of HPV as high as 90% [15]. Withal, the 
main purpose of the study was to appraise the presence of 
HPV among women undergoing vulvar sampling. 
CONCLUSIONS
Finally, it is important to gain more knowledge on vul-
var intraepithelial neoplasia as the incidence of VIN has 
Figure 1. HPV 51 positive detection on HPV Linear Assay
Table 1. Procedural modifications in patients with primary failed DNA detection 
Patient Identification Remarks for procedure protocol DNA isolation ng/uL 280/260 260/230 NO RESULT
1
1A According to protocol 432.7 1.92 2.24 No result
1B First lysis — 30 min 316.9 1.79 2.31 No result
2
2A According to protocol –7.9 –23.59 1.77 No result
2B First lysis — 30 min Second lysis — 140 uL proteinase K 1.7 2.66 –0.38 No result
3 3A According to protocol 40.5 1.44 2.06 No result
4
4A According to protocol; after deparaffinization — gel –2 –14 0.38 No result
4B First lysis — 30 min –15.2 –9.8 3.75 No result
5
5A According to protocol 16.7 1.58 4.42 No result
5B According to protocol 8.8 2.75 –1.04 No result
6
6A According to protocol 14.5 1.52 1.7 No result
6B First lysis — 30 min –14.4 –12.36 1.47 No result
7
7A According to protocol –0.6 –0.066 0.78 No result
7B First lysis — 30 min –4.7 –0.66 2.8
8
8A First lysis — 60 min 1 2.02 –0.022 No result
8B First lysis — 30 min Second lysis  —140 uL proteinase K 1.7 3.07 –0.57
Table 2. Detailed analysis of retrieved samples (VIN status, 
p53 status, p16 status)
Patient n0 VIN VIN type Age p16 p53 HPV
1 VIN1 Usual 75 focal + –
2 VIN1 Usual 58 focal + –
3 VIN1 Usual 54 + –
4 VIN3 Usual 69 + –
5 VIN1 Usual 59 – – HPV 16
6 VIN1 Usual 51 + –
7 VIN1 Usual 59 focal + –
8 VIN3 Usual 53 + –
9 VIN2 Usual 37 – focal + HPV 51
10 VIN1 Usual 66 + –
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increased in recent decades. uVIN almost doubled from 
1.2/100 000 patients in 1992 to 2.1/100 000 in 2005 and 
dVIN increased nine-fold from 0.013/100 000 patients to 
0.121/100 000 [16]. Life-time risk of HPV infection is around 
80% [17]. In light of recent findings, in which 9-valent HPV 
vaccine comparing to historic placebo proved to diminish 
by 94% incidence of vulvar or vaginal cancers, it seems 
necessary to further study the presence of HPV in women 
with vulvar intraepithelial neoplasia [18].
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